Oasmia Pharmaceutical AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more
Market Cap & Net Worth: Oasmia Pharmaceutical AB (OASMY)
Oasmia Pharmaceutical AB (PINK:OASMY) has a market capitalization of $4.12 Million ($4.12 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #40076 globally and #13022 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oasmia Pharmaceutical AB's stock price $0.02 by its total outstanding shares 206059195 (206.06 Million).
Oasmia Pharmaceutical AB Market Cap History: 2015 to 2025
Oasmia Pharmaceutical AB's market capitalization history from 2015 to 2025. Data shows change from $604.10 Million to $4.12 Million (-39.74% CAGR).
Oasmia Pharmaceutical AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oasmia Pharmaceutical AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Oasmia Pharmaceutical AB's market cap is 0.01 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $604.10 Million | $6.37 Million | -$141.54 Million | 94.79x | N/A |
| 2016 | $468.60 Million | $172.00K | -$160.24 Million | 2724.41x | N/A |
| 2017 | $149.35 Million | $3.17 Million | -$118.01 Million | 47.13x | N/A |
| 2018 | $513.38 Million | $1.98 Million | -$171.02 Million | 259.28x | N/A |
| 2019 | $225.45 Million | $201.84 Million | -$10.53 Million | 1.12x | N/A |
| 2020 | $299.22 Million | $201.84 Million | -$10.53 Million | 1.48x | N/A |
| 2021 | $167.03 Million | $26.19 Million | -$138.94 Million | 6.38x | N/A |
| 2022 | $25.35 Million | $1.01 Million | -$367.03 Million | 24.97x | N/A |
| 2023 | $41.21K | $6.61 Million | -$128.74 Million | 0.01x | N/A |
Competitor Companies of OASMY by Market Capitalization
Companies near Oasmia Pharmaceutical AB in the global market cap rankings as of March 18, 2026.
Key companies related to Oasmia Pharmaceutical AB by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Oasmia Pharmaceutical AB Historical Marketcap From 2015 to 2025
Between 2015 and today, Oasmia Pharmaceutical AB's market cap moved from $604.10 Million to $ 4.12 Million, with a yearly change of -39.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.12 Million | -60.00% |
| 2024 | $10.30 Million | +24900.00% |
| 2023 | $41.21K | -99.84% |
| 2022 | $25.35 Million | -84.83% |
| 2021 | $167.03 Million | -44.18% |
| 2020 | $299.22 Million | +32.72% |
| 2019 | $225.45 Million | -56.08% |
| 2018 | $513.38 Million | +243.74% |
| 2017 | $149.35 Million | -68.13% |
| 2016 | $468.60 Million | -22.43% |
| 2015 | $604.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Oasmia Pharmaceutical AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.12 Million USD |
| MoneyControl | $4.12 Million USD |
| MarketWatch | $4.12 Million USD |
| marketcap.company | $4.12 Million USD |
| Reuters | $4.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.